Abstracts 491 CONCLUSION: Superior clinical efficacy combined with substantial cost savings for at least one year of follow up conferred to enoxaparin a place of choice in acute cardiology therapy.
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MEDTAP, London, UK; 2 MEDTAP International, Inc, London, UK; 3 City Hospital, Nottingham, UK OBJECTIVE: To conduct an economic analysis of the PURSUIT trial in the UK for patients with unstable angina or non-Q-wave myocardial infarction (MI) admitted to hospital and randomized to eptifibatide (GPIIb/IIIa) or placebo in addition to usual therapy. METHODS: Health-care resource consumption was collected prospectively for all patients in the PURSUIT trial. Unit costs were developed for the UK and applied to the resources consumed in the trial to estimate the cost per patient treated during index hospital stay and at six months follow-up. Analyses were conducted using resource consumption from the UK sub population, Western European (WE) sub population, and the total PURSUIT trial population. Long term outcome measures were based on life expectancy estimated from six-month PURSUIT data of the WE sub-population and the North American (NA) ϩ WE sub populations. RESULTS: Initial hospital and six-month costs for eptifibatide patients including drug cost were slightly higher than the placebo group using the WE and overall trial population resources. UK-specific resource consumption was lower in the eptifibatide group. The difference in 30day rate of death and MI was 1% (NS) for WE and 1.5% (p ϭ 0.04) for the overall trial. At six months, MI rates were further decreased for eptifibatide but no difference existed in mortality between the groups. The CE ratios (discounted at 3%) using WE or overall resources are £8,436 and £12,591 respectively using WE survival or £3,418 and £5,036 using WE ϩ NA survival. Using UK resources, eptifibatide is cost saving in either survival scenario. CONCLUSION: The cost-effectiveness ratios for eptifibatide in the UK all fall within an acceptable range for adopting new technology. The impact of resource consumption data on the cost-effectiveness ratio underscores the importance of the source of treatment-pattern data and the need for prospective or retrospective data collection to reflect country-management styles. 
METHODS:
A decision-tree model was constructed to determine the total expected cost per patient for a fourmonth time period following an initial angioplasty. The model used clinical data from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES), a four-month, multicenter, double-blind, placebo-controlled trial conducted to investigate the effect of amlodipine on restenosis and clinical events in patients undergoing PTCA. Clinical endpoints of interest included MI, repeat PTCA, CABG, and all-cause mortality. Clinical experts from Canada and Norway were enlisted and a modified Delphi study approach was used to estimate the amount of health-care resources consumed for each clinical outcome. RESULTS: The adjunctive use of amlodipine improved the four-month success rate of angioplasties by 9.4% (83.7% vs 93.1%). In other words, there was a decrease in the number of adverse clinical endpoints after an angioplasty. There was an absolute reduction of 2.0%, 4.7%, and 2.7% in the rate of MI, PTCA, and CABG, respectively. The total expected cost per patient using amlodipine was $6,398 (US$4, 328) in Canada and kr35,652 (US$4,004) in Norway. The total expected cost per patient not using amlodipine was $6,519 (US$4, 410) in Canada and kr37, 150 (US$4, 172) in Norway. The model demonstrated the magnitude of the potential savings resulting from the improved clinical outcomes for patients using amlodipine with PTCA. Overall, fewer health resources were utilized by amlodipine patients, resulting in savings in total expected cost of treatment of $121 (US$82) in Canada and kr1, 498(US$168) in Norway. CONCLUSIONS: The adjunctive use of amlodipine is a cost-effective therapeutic strategy to achieve more favorable clinical outcomes in patients undergoing PTCAs in Canada and Norway.
